New drug trial for kids with severe psoriasis shows promise
NCT ID NCT03240809
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a single dose of brodalumab in children aged 6 to 17 with severe plaque psoriasis. The goal is to see how safe the drug is and how the body processes it. Only 2 children are enrolled, making this a very early look at the drug's effects in younger patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brodalumab
What this could lead to
If successful, this could provide a treatment option for children with severe psoriasis, helping to control their symptoms.
What could go wrong
This is a very small, early-phase study with only 2 participants, so results may not apply to all children. The drug may cause side effects or not work as expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bausch Site 001
Las Vegas, Nevada, 45242, United States
-
Bausch Site 002
Miami, Florida, 33155, United States
-
Bausch Site 003
San Diego, California, 92123, United States
-
Bausch Site 004
Miami, Florida, 33155, United States
-
Bausch Site 005
Henderson, Nevada, 89052, United States